Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

Abstract

The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.

Keywords: Cardio-oncology; Cardiomyopathy; Cardiotoxicity; Hypertension; Myocarditis; QTc prolongation; Vascular disease.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Figures

Graphical Abstract

Outline of the five focus areas of cardiovascular toxicities covered in this definitions document. HF, heart failure.

Figure 1

PubMed entries over time for case reports, clinical, observational, or multicentre studies, and randomized controlled clinical trials based on the following search terms: cardiotoxicity OR cardiac dysfunction OR cardiomyopathy OR heart failure AND cancer, myocarditis AND cancer, vascular toxicity OR atherosclerosis OR thrombosis OR vasospasm AND cancer, hypertension AND cancer, pericarditis OR pericardial disease AND cancer, valvular heart disease AND cancer.

Figure 2

Diagnostic algorithm for cancer therapy-related cardiac dysfunction. GLS, global longitudinal strain; HF, heart failure; LVEF, left ventricular ejection fraction.

Figure 3

Overview of the approach to QTc prolongation in cancer patients. CV, cardiovascular; LVEF, left ventricular ejection fraction; QTcF, QT interval corrected by the Fridericia formula.